News

Reimbursement Agreement Includes Orkambi in Public Health Plan for CF Patients in Australia

Beginning Oct. 1, the cystic fibrosis (CF) targeted therapy Orkambi (lumacaftor/ivacaftor) will be included on Australia’s Pharmaceutical Benefits Scheme. The Australian government’s decision resulted from the completion of an agreement with Orkambi’s manufacturer, Vertex Pharmaceuticals, and was supported by the recent positive recommendation from the Pharmaceutical Benefits Advisory Committee…

Vertex, Genomics Team Up in Quest for Genetics-based, Precision Medicines

Vertex Pharmaceuticals and Genomics announced a three-year collaboration to better understand genetic variations and their effect on clinical outcomes of diseases with unmet therapeutic needs, including cystic fibrosis. The collaboration also will promote the development of precision medicine, an approach to customize treatment based on each patient’s genetic…